Summary
There is a need for cost-effective molecular point of care diagnostic tools to provide better healthcare to patients and better agility to our healthcare system. And what about going one step further by extending the limits of molecular diagnostics to the nano-scale?
The market needs a rapid and definitive answer at entry level. Needs a diagnostic that is capable of screen directly and simply hundreds of samples with low infrastructure and low-grade people, that can rely on existing peripheral infrastructure like peripheral hospital and microscopy centres.
We have developed the nano-technology-based solution NANO4. NANO4 is a fast and user-friendly nano-based diagnostic technology suitable for use at the Point of Need. NANO4 represents a highly specific and sensitive nanotechnology for in vitro molecular diagnostics. It uses gold nano-probes to recognize the complementary DNA/RNA strand and yield a colour output that allows for quick decision making.
Molecular diagnosis is a multi-million Euro market and making use of our SME Instrument Phase 1 Feasibility Study, we defined our go-to-market roadmap for our first disruptive products: NANO4 TB for Tuberculosis, and NANO4 CML for Chronic Myeloid Leukaemia, including industrial scale-up and CE mark.
We have already established partnerships with distributors in Europe and Brazil, and our technology has been referenced by FIND as a promising new solution for TB diagnosis. We have also established a connection with the World Health Organization, in order to obtain an endorsement as soon as we receive the CE mark.
NANO4 was founded in end 2015, and we have raised €200.000 from Business Angels and have already begun our operations to take our products to the market, expecting a Series A at the end of 2018.
With the successful conclusion of this project, NANO4 will become one of the few companies in Europe to possess nanotechnology capacities at industrial scale, focused on the life sciences sector.
The market needs a rapid and definitive answer at entry level. Needs a diagnostic that is capable of screen directly and simply hundreds of samples with low infrastructure and low-grade people, that can rely on existing peripheral infrastructure like peripheral hospital and microscopy centres.
We have developed the nano-technology-based solution NANO4. NANO4 is a fast and user-friendly nano-based diagnostic technology suitable for use at the Point of Need. NANO4 represents a highly specific and sensitive nanotechnology for in vitro molecular diagnostics. It uses gold nano-probes to recognize the complementary DNA/RNA strand and yield a colour output that allows for quick decision making.
Molecular diagnosis is a multi-million Euro market and making use of our SME Instrument Phase 1 Feasibility Study, we defined our go-to-market roadmap for our first disruptive products: NANO4 TB for Tuberculosis, and NANO4 CML for Chronic Myeloid Leukaemia, including industrial scale-up and CE mark.
We have already established partnerships with distributors in Europe and Brazil, and our technology has been referenced by FIND as a promising new solution for TB diagnosis. We have also established a connection with the World Health Organization, in order to obtain an endorsement as soon as we receive the CE mark.
NANO4 was founded in end 2015, and we have raised €200.000 from Business Angels and have already begun our operations to take our products to the market, expecting a Series A at the end of 2018.
With the successful conclusion of this project, NANO4 will become one of the few companies in Europe to possess nanotechnology capacities at industrial scale, focused on the life sciences sector.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/822932 |
| Start date: | 01-07-2018 |
| End date: | 31-12-2021 |
| Total budget - Public funding: | 2 028 900,00 Euro - 1 420 230,00 Euro |
Cordis data
Original description
There is a need for cost-effective molecular point of care diagnostic tools to provide better healthcare to patients and better agility to our healthcare system. And what about going one step further by extending the limits of molecular diagnostics to the nano-scale?The market needs a rapid and definitive answer at entry level. Needs a diagnostic that is capable of screen directly and simply hundreds of samples with low infrastructure and low-grade people, that can rely on existing peripheral infrastructure like peripheral hospital and microscopy centres.
We have developed the nano-technology-based solution NANO4. NANO4 is a fast and user-friendly nano-based diagnostic technology suitable for use at the Point of Need. NANO4 represents a highly specific and sensitive nanotechnology for in vitro molecular diagnostics. It uses gold nano-probes to recognize the complementary DNA/RNA strand and yield a colour output that allows for quick decision making.
Molecular diagnosis is a multi-million Euro market and making use of our SME Instrument Phase 1 Feasibility Study, we defined our go-to-market roadmap for our first disruptive products: NANO4 TB for Tuberculosis, and NANO4 CML for Chronic Myeloid Leukaemia, including industrial scale-up and CE mark.
We have already established partnerships with distributors in Europe and Brazil, and our technology has been referenced by FIND as a promising new solution for TB diagnosis. We have also established a connection with the World Health Organization, in order to obtain an endorsement as soon as we receive the CE mark.
NANO4 was founded in end 2015, and we have raised €200.000 from Business Angels and have already begun our operations to take our products to the market, expecting a Series A at the end of 2018.
With the successful conclusion of this project, NANO4 will become one of the few companies in Europe to possess nanotechnology capacities at industrial scale, focused on the life sciences sector.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
